PMV

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

Retrieved on: 
Mercoledì, Maggio 29, 2024
NCT, Partnership, Patient, DNA, CDX, Food, PMV, Prevalence, Clinical trial, FDA, TP53, Cancer, Fast Track, Foundation Medicine, Mutation, Physician, Pharmaceutical industry

“We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”

Key Points: 
  • “We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”
    Rezatapopt (PC14586) is an investigational, first-in-class, selective p53 reactivator designed to stabilize p53 Y220C proteins.
  • The TP53 Y220C mutation creates a small pocket in the p53 protein, making it thermally unstable and unable to effectively interact with DNA.
  • If the CDx and separately the therapy are approved, FoundationOne CDx would be the first companion diagnostic to identify patients with TP53 Y220C mutations who may be eligible for rezatapopt.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

Retrieved on: 
Mercoledì, Maggio 29, 2024
Science, Other Science, Research, Pharmaceutical, Medical Supplies, Oncology, Health, FDA, NCT, Partnership, Patient, DNA, CDX, Food, PMV, Prevalence, Clinical trial, TP53, Fast Track, Foundation Medicine, Mutation, Physician, Pharmaceutical industry

“We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”

Key Points: 
  • “We’re proud to provide our high-quality tissue-based genomic test, along with real-world data from our Flatiron Health-Foundation Medicine Clinico-Genomic Database, to support PMV Pharma as they develop this exciting new treatment option.”
    Rezatapopt (PC14586) is an investigational, first-in-class, selective p53 reactivator designed to stabilize p53 Y220C proteins.
  • The TP53 Y220C mutation creates a small pocket in the p53 protein, making it thermally unstable and unable to effectively interact with DNA.
  • If the CDx and separately the therapy are approved, FoundationOne CDx would be the first companion diagnostic to identify patients with TP53 Y220C mutations who may be eligible for rezatapopt.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
PMV, Research, Pembrolizumab, Merck & Co., Patient, Merck, Pharmaceutical industry

“Dosing the first patient in the registrational, tumor-agnostic Phase 2 portion of the PYNNACLE trial was an important milestone for PMV.

Key Points: 
  • “Dosing the first patient in the registrational, tumor-agnostic Phase 2 portion of the PYNNACLE trial was an important milestone for PMV.
  • Net loss for the quarter ended March 31, 2024, was $15.3 million compared to $19.1 million for the quarter ended March 31, 2023.
  • Research and development (R&D) expenses were $13.2 million for the quarter ended March 31, 2024, compared to $15.1 million for the quarter ended March 31, 2023.
  • General and administrative (G&A) expenses were $5.0 million for the quarter ended March 31, 2024, compared to $6.4 million for the quarter ended March 31, 2023.

Transparency Notifications from Shareholders

Retrieved on: 
Mercoledì, Aprile 3, 2024
Disclosure, PMV, Financial services, Person, FSMA, Security (finance)

(1) The total number of outstanding shares of the Company mentioned in the relevant transparency notifications amounts to 35,909,420, each share giving right to one (1) vote (being 35,909,420 voting rights in total).

Key Points: 
  • (1) The total number of outstanding shares of the Company mentioned in the relevant transparency notifications amounts to 35,909,420, each share giving right to one (1) vote (being 35,909,420 voting rights in total).
  • The notification furthermore specifies that PMV is controlled by Het Vlaams Gewest and that Het Vlaams Gewest is not controlled.
  • (4) If the holding has fallen below the lowest threshold, the shareholder doesn’t have to report the number of shares and voting rights held.
  • To access copies of the aforementioned transparency notifications, reference is made to Sequana Medical's website ( https://www.sequanamedical.com/investors/shareholder-information/ ).

MICLEDI Microdisplays Raises Series A Funding to Advance Best-in-Class microLED Display Design and Manufacturing

Retrieved on: 
Martedì, Marzo 12, 2024
CMOS, Aluminium gallium indium phosphide, ASIC, Augmented reality, Application-specific integrated circuit, SPIE, KBC, Tier 1, RGB, GF, PMV, CES, Series, GlobalFoundries, MicroLED, Television

Series A follows a significant seed round award and additional non-dilutive funding in the form of grants and other vehicles from VLAIO.

Key Points: 
  • Series A follows a significant seed round award and additional non-dilutive funding in the form of grants and other vehicles from VLAIO.
  • This brings the company’s total funding to date to nearly $30 million.
  • “The company’s achievements during this seed round have been astounding,” said Sean Lord, CEO of MICLEDI.
  • Seed funding also enabled the company to prove best-in-class blue and green GAN-based microLED arrays with pixel-by-pixel microlenses in its unique 300mm flow.

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Retrieved on: 
Giovedì, Gennaio 18, 2024
PMV, Workforce

PMV will maintain a focused discovery research effort and expects that the resulting savings in operating expenses will extend its cash runway to the end of 2026.

Key Points: 
  • PMV will maintain a focused discovery research effort and expects that the resulting savings in operating expenses will extend its cash runway to the end of 2026.
  • As of December 31, 2023, on an unaudited basis, PMV had approximately $229 million in cash, cash equivalents, and marketable securities.
  • “We are grateful for their dedication and contributions to help bring PMV and PC14586 to this point of development.
  • This is a difficult but necessary step to ensure that PC14586 is developed as efficiently as possible to benefit patients.”

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Retrieved on: 
Venerdì, Gennaio 5, 2024
CFO, Pharming, CDO, PMV, Facility, General counsel, Growth, Human resources, Corporate development, G&A, Senior, Management

(Senior Vice President, Head of Clinical Development and Medical Affairs)

Key Points: 
  • (Senior Vice President, Head of Clinical Development and Medical Affairs)
    PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team.
  • Dr. Jalota joined PMV in 2019 and was promoted to Chief Development Officer (CDO) in May 2023.
  • Dr. Fellous joined PMV in 2022 and was promoted to Senior Vice President, Clinical Development and Medical Affairs in May 2023.
  • I also want to congratulate Mike, Rob, and Tim in their new and expanded roles at PMV.

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Giovedì, Novembre 9, 2023
Neoplasm, FDA, Research, Recommended maximum intake of alcoholic beverages, AACR, ATM, Food, Pembrolizumab, Endometrial cancer, Conference, Merck, PMV, KRAS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Poster, Pharmacokinetics, Clinical trial, KOL, Merck Sharp & Dohme Federal Credit Union, Mass, Safety, Patient, Breast, Prostate, Merck & Co., Pharmaceutical industry, Cryptocurrency, G&A

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • We look forward to initiating a registrational Phase 2 study in the first quarter of 2024.”
    Third Quarter 2023 and Recent Corporate Highlights:
    Updated clinical results from the Phase 1 PYNNACLE study evaluating PC14586 were featured in a late-breaking poster at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 12, 2023.
  • A copy of the poster can be found on the PMV corporate website here .
  • General and administrative (G&A) expenses were $18.7 million for the nine months ended September 30, 2023, compared to $18.9 million for the nine months ended September 30, 2022.

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Retrieved on: 
Giovedì, Ottobre 12, 2023
Food, September 5, Pharmacokinetics, Female, KRAS, Memorial Sloan Kettering Cancer Center, Vomiting, Breast, AACR, ORR, Chemistry, KOL, TP53, Safety, Mutation, Mass, Endometrial cancer, Nausea, Therapy, RECIST, PMV, Recommender system, Clinical trial, Trae tha Truth, Lung, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Prostate, Conference, Patient, Phase II, Medical imaging, Pharmaceutical industry, Medical device, Birth control, Cancer

Dr. Schram commented, “Patients with a solid tumor harboring a TP53 Y220C mutation are in need of new treatment options, as currently there are no approved therapies targeting p53.

Key Points: 
  • Dr. Schram commented, “Patients with a solid tumor harboring a TP53 Y220C mutation are in need of new treatment options, as currently there are no approved therapies targeting p53.
  • Confirmed responses were observed in patients whose tumors were TP53 Y220C and KRAS wild-type in the efficacious dose range, in multiple tumor types including ovarian, breast, prostate, small-cell lung, and endometrial cancer.
  • The planned Phase 2 patient population includes TP53 Y220C and KRAS wild-type patients.
  • The emerging Phase 1 data have guided us in designing our Phase 2 registrational trial to enroll a TP53 Y220C and KRAS wild-type patient population.

ClearVue Solar Glazing System Offers Up To 71% Offset of Building Energy Consumption

Retrieved on: 
Giovedì, Ottobre 5, 2023
Carbon, Government, Building, CO2, Society, ASHRAE, IGU, DGU, Glare, Internal, PMV, Building and Construction Authority, Igus, CPV, Skylab, BCA, Construction, Renewable energy, Property management, Heating, ventilation, and air conditioning

PERTH, Australia, Oct. 5, 2023 /PRNewswire-PRWeb/ -- Smart building materials company ClearVue Technologies Limited (ClearVue – ASX: CPV | OTC: CVUEF) announces results from Singapore's Building and Construction Authority's SkyLab test facility which concluded significant energy generation, savings, and sustainability benefits of ClearVue Solar IGUs especially when deployed in conjunction with ClearVue's Solar Spandrel solution.

Key Points: 
  • The notable outcomes from the real-world testing of ClearVue IGUs include:
    Energy Performance of ClearVue Solar IGUs:
    22.8% reduction in cooling load, resulting in 7.5% overall energy savings including energy generation from ClearVue IGUs.
  • Total building energy consumption (from cooling, lights, fans, and plug loads) averaged 6.1% lower than a conventional building faGade excluding generation.
  • When accounting for the emissions offset through solar power generation as well, the ClearVue Solar IGUs provide an estimated 4.75-year carbon payback period.
  • Energy Performance of ClearVue solar IGUs and Spandrel Solution:
    71% overall energy savings achieved when combining ClearVue solar IGUs and spandrel.